Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» ACC: Novartis' canakinumab cuts CV risks in patients with kidney disease, diabetes by up to 18%
ACC: Novartis' canakinumab cuts CV risks in patients with kidney disease, diabetes by up to 18%
ACC: Novartis' canakinumab cuts CV risks in patients with kidney disease, diabetes by up to 18%
Submitted by
admin
on March 13, 2018 - 11:43am
Source:
Fierce Pharma
News Tags:
Novartis
canakinumab
kidney disease
ACC
Headline:
ACC: Novartis' canakinumab cuts CV risks in patients with kidney disease, diabetes by up to 18%
Do Not Allow Advertisers to Use My Personal information
